clinical trial · NCT06976190
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Recurrent or Metastatic Nasopharyngeal CarcinomaMRG003 + PucotenlimabGemcitabine, Docetaxel, or Capecitabine
brief summary
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
started
May 6, 2025
primary completion
May 1, 2029
completion
Dec 1, 2030
last updated
Jan 20, 2026
official title
A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol